Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01465893
Other study ID # isfahan medical university
Secondary ID
Status Recruiting
Phase Phase 2
First received October 28, 2011
Last updated November 21, 2011
Start date July 2011
Est. completion date December 2012

Study information

Verified date November 2011
Source Isfahan University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ethics Committee
Study type Interventional

Clinical Trial Summary

This study examines the effect of vitamin D on Retinal changes in patient with optic Neuritis.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2012
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Both
Age group 15 Years to 50 Years
Eligibility Inclusion Criteria:

- age 15-50 years

- no history of demyelinative events

- level of vitamin d below 20 ng/ml

- no pass 10-32 day from starting symptom

Exclusion Criteria:

- using vitamin D supplement

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Vitamin D
vitamin D ,50000 unit /week
Vitamin D withheld
do not receive anything

Locations

Country Name City State
Iran, Islamic Republic of Isfahan Medical University Tehran

Sponsors (1)

Lead Sponsor Collaborator
Isfahan University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary measurement Retinal nerve fiber layer (RNFL) thickness by OCT 10-32 days after optic neuritis Yes
Secondary measurement RNFL thickness by OCT 6 months after optic neuritis Yes
See also
  Status Clinical Trial Phase
Unknown status NCT00261326 - Simvastatin Treatment of Patients With Acute Optic Neuritis Phase 3
Active, not recruiting NCT03963310 - Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
Recruiting NCT03586557 - Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis N/A
Recruiting NCT05487989 - VIsual Pathways Model in Neuro-inflammatory Disorders
Terminated NCT04131764 - Diagnosis of ON With or Without MS or NMOSD
Not yet recruiting NCT06453694 - Efgartigimod for the Treatment of Acute Optic Neuritis Phase 2
Completed NCT01962571 - Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Phase 3
Recruiting NCT03302585 - High-Dose Vitamin D Induction in Optic Neuritis Phase 2
Recruiting NCT02886377 - The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset N/A
Completed NCT01987167 - Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis Early Phase 1
Completed NCT01451593 - Neuroprotection With Phenytoin in Optic Neuritis Phase 2
Completed NCT03630497 - BN201 SAD MAD Study in Healthy Subjects Phase 1
Completed NCT01337986 - Ampyra for Optic Neuritis in Multiple Sclerosis Phase 2/Phase 3
Completed NCT01274702 - Visual Reconstitution Therapy After Optic Neuritis Phase 2
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Withdrawn NCT00037115 - Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Phase 4
Not yet recruiting NCT06389968 - Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis N/A
Recruiting NCT04257734 - Epidemiologic and Clinical Characteristics of Optic Neuritis in China
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Completed NCT02939937 - Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis Phase 2